Timothy L. Comstock

Medicine · Health Sciences

24h-index2.6kcitations72works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ocular Infections and Treatments(40), Ocular Surface and Contact Lens(23), Intraocular Surgery and Lenses(22), Glaucoma and retinal disorders(18), Antibiotics Pharmacokinetics and Efficacy(15)

Publications72 total

Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid
Expert Opinion on Pharmacotherapy·2018· 49 citedOpen Access
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
Advances in Therapy·2016· 103 citedOpen Access
Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis
Ocular Immunology and Inflammation·2016· 10 citedOpen Access
Zylet (loteprednol etabonate 0.5%/tobramycin 0.3%) Compared with Tobradex (dexamethasone 0.1%/tobramycin 0.3%) for the treatment of blepharitis in a large international population
Investigative Ophthalmology & Visual Science·2015
Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
Clinical ophthalmology·2015· 5 citedOpen Access
Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population
Ophthalmology and Therapy·2014· 50 citedOpen Access
Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution
Asia-Pacific Journal of Ophthalmology·2014· 4 citedOpen Access
An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
Clinical ophthalmology·2014· 44 citedOpen Access
Antibacterial Susceptibility of Coagulase Negative Staph Before and After Prophylactic Use of Besifloxacin and Moxifloxacin
Investigative Ophthalmology & Visual Science·2014
Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens
Clinical Optometry·2014· 2 citedOpen Access
Loteprednol Etabonate Ophthalmic Gel 0.5% Following Cataract Surgery: Integrated Analysis of Two Clinical Studies
Advances in Therapy·2013· 11 cited
Zylet (loteprednol etabonate 0.5%/tobramycin 0.3%) Compared with Tobradex (dexamethasone 0.1%/tobramycin 0.3%) for the Treatment of Lid Inflammation in Two Populations
Investigative Ophthalmology & Visual Science·2013
Atypical Pathogens Observed in Recent Clinical Studies of Bacterial Conjunctivitis
Investigative Ophthalmology & Visual Science·2013· 1 cited
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
Clinical ophthalmology·2012· 18 citedOpen Access
Microbiological Eradication Rates with BID or TID Dosing of Besifloxacin Ophthalmic Suspension, 0.6% in Bacterial Conjunctivitis Clinical Trials from 2004 - 2010
Investigative Ophthalmology & Visual Science·2012
Clinical efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against MRSA and MRSE
Investigative Ophthalmology & Visual Science·2012· 1 cited
Clinical Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against Less Common Conjunctivitis Pathogens of Ophthalmic Interest
Investigative Ophthalmology & Visual Science·2012
Clinical Efficacy Of Loteprednol Etabonate Gel 0.5% In The Treatment Of Ocular Inflammation And Pain After Cataract Surgery
2012
Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis in Adults and Children
Clinical Drug Investigation·2012· 26 cited
Safety and Tolerability of Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension in Pediatric Subjects
Pediatric Drugs·2012· 23 cited
page 1 of 4Next →

Frequent Co-authors

Dale W. Usner(12), Michael R. Paterno(12), Timothy W. Morris(10), Heleen H. DeCory(7), David Callanan(5), P. Andrew Pearson(5), Paul A. Erickson(5), Brian Levy(4), Kirk Bateman(4), Lynne S. Gearinger(4), Glenn J. Jaffe(3), John D. Sheppard(3), Lynne S. Brunner(3), Paul Karpecki(3), Joel W. Proksch(3), Edward J. Holland(3), Bruce E. Silverstein(3), Daniel Martín(2), Wolfgang Haas(2), Eric M. White(2)